0001171843-13-003728.txt : 20130917 0001171843-13-003728.hdr.sgml : 20130917 20130917060155 ACCESSION NUMBER: 0001171843-13-003728 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130917 FILED AS OF DATE: 20130917 DATE AS OF CHANGE: 20130917 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RedHill Biopharma Ltd. CENTRAL INDEX KEY: 0001553846 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35773 FILM NUMBER: 131099956 BUSINESS ADDRESS: STREET 1: 21 HA'ARBA'A STREET CITY: TEL AVIV STATE: L3 ZIP: 64739 BUSINESS PHONE: 972-3-541-3131 MAIL ADDRESS: STREET 1: 21 HA'ARBA'A STREET CITY: TEL AVIV STATE: L3 ZIP: 64739 6-K 1 f6k_091713.htm FORM 6-K f6k_091713.htm
UNITED STATES   
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K
  
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
For the month of September 2013
Commission File No.:001-35773
 
REDHILL BIOPHARMA LTD.
(Translation of registrant’s name into English)

21 Ha'arba'a Street, Tel Aviv, 64739, Israel
 (Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

Form 20-F S Form 40-F £
 
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ 
 
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ 

Mr. Dror Ben-Asher, the Company's Chief Executive Officer, presented an overview of the Company at the Annual Stifel Nicolaus Healthcare Conference held in Boston on Thursday, September 12, 2013. A copy of the presentation made by the Company as well as a webcast replay of the presentation have been archived on the Company's website and may be viewed at the following web address: http://ir.redhillbio.com/events.cfm. The webcast replay will be available on RedHill's website for 30 days.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286).

Signatures
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 


 
 
 
Date: September 17, 2013
  
REDHILL BIOPHARMA LTD.
(the "Registrant")
 
By: /s/ Dror Ben-Asher
——————————————
Dror Ben-Asher
Chief Executive Officer